Supplementary

**Figure S1** Kaplan-Meier plots for OS in patients with bone metastatic LADC according to combination CTx. The OS did not differ significantly between patients treated with PC vs. GC or EC (median OSs were 8.1 vs. 12.4 months, respectively; P=0.297, log-rank test). BTx, bisphosphonate therapy; LADC, lung adenocarcinoma; OS, overall survival; PC, paclitaxel and carboplatin; GC, gemcitabine and cisplatin; EC, etoposide and cisplatin.

**Figure S2** Kaplan-Meier estimates for OS in bone metastatic LADC patients according to different generations of BTx. LADC patients receiving second-generation BTx had significantly increased median OS (vs. those treated with first-generation BTx, median OSs were 13.2 vs. 7.1 months, respectively; P=0.041, Gehan-Breslow-Wilcoxon test). BTx, bisphosphonate therapy; LADC, lung adenocarcinoma; OS, overall survival.